Hepatitis C Articles (HCV)
Back
	GT-3 - Here are several studies       Daclatasvir+SOF Ally-3+   SOF/Vel without RBV/ASTRAL-3, and a 2nd small study with Rbv.   SOF/Vel+GS-9857   Harvoni with & without RBV   AASLD: Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV-Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study - (11/30/15)   AASLD: Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-Infected Patients - (11/16/15)   AASLD: All-Oral Treatment With Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+ Phase 3 Study - (11/23/15) Genotype 3 at AASLD - (01/11/16)   without RBV, SOF/Vel & SOF/Vel+GS-9857: High Efficacy of Treatment With Sofosbuvir + GS-5816 ± Ribavirin for 12 Weeks in Treatment-Experienced Patients With Genotype 1 or 3 HCV Infection - (11/12/14) Therapy With Direct-Acting Antivirals for Genotype 3 Patients: Interferon's Last Gasp? Commentary.....http://www.natap.org/2015/HCV/110415_02.htm           View Older Articles   Back to Top   www.natap.org